Fractionated carboplatin radiosensitization: A phase I dose-escalation study

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 21, Issue 6, 1998, Pages 595-601

  Koukourakis, Michael I ^a   Stefanaki, Irene ^a   Giatromanolaki, Alexandra ^a   Frangiadaki, Chryssi ^a   Armenaki, Athena ^a   Georgoulias, Vassilios ^a   Koumandakis, Eugenios ^a   Kranidis, Angelos ^a   Helidonis, Emmanuel ^a  

^a UNIVERSITY HOSPITAL OF IRAKLION   (Greece)

Author keywords

Amifostine; Carboplatin; Dose escalation; Radiosensitization; Radiotherapy

Indexed keywords

AMIFOSTINE; CARBOPLATIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; COHORT ANALYSIS; DOSE CALCULATION; DOSE RESPONSE; DRUG TOLERANCE; FEMALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA; PELVIS TUMOR; PHASE 1 CLINICAL TRIAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIOSENSITIZATION; VOMITING;

ADULT; AGED; AMIFOSTINE; ANTINEOPLASTIC AGENTS; CARBOPLATIN; COMBINED MODALITY THERAPY; ERYTHROPOIETIN, RECOMBINANT; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PELVIC NEOPLASMS; RADIATION-PROTECTIVE AGENTS; RADIATION-SENSITIZING AGENTS;

EID: 0031737547     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199812000-00013     Document Type: Article

References (28)

1. Douple EB, Richmond RC, O'Hara JA, Coughlin CT. Carboplatin as a potentiator of radiation therapy. Cancer Treat Rev 1991;12:111-24.
2. Skov K, McPhails S. Interaction of platinum drugs with clinically relevant x-ray doses in mammalian cells: a comparison of cisplatin, carboplatin, iproplatin and tetraplatin. Int J Radiat Oncol Biol Phys 1991;20:221-5.
3. Bishop IF, Ball D, Crennan E, et al. Radiation and carboplatin combined-modality therapy in non-small cell lung cancer. Semin Oncol 1994;21(suppl 6):91-6.
4. Muggia FM, Muderpach L. Platinum compounds in cervical and endometrial cancers: focus on carboplatin. Semin Oncol 1994;21(suppl 2):35-41.
5. Zamboglou N, Schnabel T, Kolottas C, et al. Carboplatin and radiotherapy in the treatment of head and neck cancer: six years' experience. Semin Oncol 1994;21(suppl 12):45-53.
6. Oguri S, Sakakibara T, Mase H, et al. Clinical pharmacokinetics of carboplatin. J Clin Pharmacol 1988;28:208-15.
7. Fowler JF. Intervals between multiple tractions per day. differences between early and late reactions. Acta Oncol 1988;27:181-3.
8. Fowler JF. Fading times required for apparently complete repair in irradiated tissue assuming the linear quadratic model of dose response. Int J Radiat Biol 1987;50:601-7.
9. Thames HD, Withers HP, Peters LJ. Tissue repair capacity and repair kinetics deduced from multifractionated or continued irradiation regimens with incomplete repair. Br J Cancer 1984;48(suppl VI):263-9.
10. Koukourakis M, Hlouverakis G, Kosma L, Skarlatos J, Damilakis J, Giatromanolaki A, Yannakakis D. The impact of overall treatment time on the results of radiotherapy for non small cell lung cancer. Int J Radiat Oncol Biol Phys 1996;34:315-22.
11. Maciejewski B, Majewski S. Dose fractionation and tumor repopulation in radiotherapy for bladder cancer. Radiother Oncol 1991;21:163-70.
12. World Health Organization. Handbook for reporting results of cancer treatment. Geneva: World Health Organization Offset Publication, 1979;48.
13. Douple EB, Ealton WL, Tulloh ME. Skin radiosensitisation studies using combined cis-dichlorodiammineplatinum (I) and radiation. Int J Radiat Oncol Biol Phys 1979;5:1383-5.
14. Tanabe M, Godat D, Kallman RF. Effects of fractionated schedules of irradiation combined with cis-diamminedichloroplatinum II on SCCVII/St tumor and normal tissue of the C3H/KM mouse. Int J Radiat Oncol Biol Phys 1987;13:1523-32.
15. Douple EB, Tohen MD, Spencer F. Platinum levels in murin tumor following intraperitoneal administration of cisplatin or paraplatin. Natl Cancer Inst Monogr 1988;6:129-32.
16. Tannock IF. Combined modality treatment with radiotherapy and chemotherapy. Radiother Oncol 1989;16:83-101.
17. Belani CP, Aisner J. Combined chemotherapy and radiation in locally advanced non-small cell lung cancer. Semin Oncol 1994;21(suppl 6):79-90.
18. Ansari R, Takars R, Fisher W, et al. A phase III study of thoracic irradiation with or without concomitant cisplatin in locoregional unresectable non-small cell lung cancer (NSCLC): a hoosier oncology group (HOG) protocol [abstract A823]. Proceedings of the American Society of Clinical Oncology 1991;10:141.
19. Skarlatos J, Kosma L, Koukourakis M, et al. A feasibility study on hypofractionated radiotherapy with concurrent 5-fluorouracil radiosensitization for recurrent or locally advanced colorectal cancer. Int J Colorectal Dis 1996;11:206-10.
20. Kosma L, Koukourakis M, Skarlatos J, Zambatis C, Ardavanis A, Mperoukas K, Yannakakis D. Hypofractionated radiotherapy with 5-fluorouracil radiosensitization for locally "far advanced" breast cancer. Am J Clin Oncol 1997;20:562-6.
21. Fletcher GH. Hypofractionation: lessons from complications. Radiother Oncol 1991;20:10-5.
22. Groen HJM, vander Leest AHD, deVries EGE, Yges DRA, Szabo BG, Mulder NH. Continuous carboplatin infusion during 6 weeks' radiotherapy in locally inoperable non-small cell lung cancer: a phase I and pharmacokinetic study. Br J Cancer 1995;72:992-7.
23. Budd GT, Ganapathi R, Kukowski RM, Murthy S. Clinical effects of Amifostin (Ethyol@) in patients treated with carboplatin. Eur J Cancer 1996;32(suppl 4):S43-5.
24. Koukourakis M, Saunders M, O'Byrne K, Mccauley V, Talbot DC, Harris AL. A pilot study of cyclophosphamide, methotrexate and infusional 5-fluorouracil for metastatic breast cancer. Br J Cancer 1998; in press.
25. Yang LX, Douple EB, Wang HJ. Irradiation enhances cellular uptake of carboplatin. Int J Radiat Oncol Biol Phys 1995;33:641-6.
26. Bukowski RM. The need for cytoprotection. Eur J Cancer 1996;32(suppl 4):S2-S4.
27. Liu T, Liu Y, He S, Zhang Z, Kligerman MM. Use of radiation with or without WR-2721 in advanced rectal cancer. Cancer 1992;69:2820-5.
28. Wasserman TH. Radiotherapeutic studies with Amifostin (ETHYOL). Semin Oncol 1994;21(suppl 11):21-5.